Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Oct 2, 2026
Reporting period
Not applicable
Filed with the SEC
Oct 6, 2026
OfficerOption exercise
Context
Classification
option exercise
Code M — exercise or conversion of a derivative security
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001193125-26-414688
Filed / recorded
Oct 6, 2026, 3:58 AM UTC
Added to OQRO
Oct 6, 2026, 7:14 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
CORCEPT THERAPEUTICS INC
Issuer CIK
1088856
Ticker
CORT
Reporting person
Roberto Wandenkolk Vieira
Relationship
Officer
Officer title
President, Oncology
Security
Common Stock
Table
Non-derivative (Table I)
Transaction date
Oct 2, 2026
Transaction code
M
Shares / units
8,333
Price per share
$21.63
Acquired / disposed
Acquired (A)
Shares owned after
12,279
Ownership form
Direct
Amendment
No
Footnotes from the filing
Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 634 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 138 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.